KR20190038679A - 칼슘 유동 작동제 및 이의 방법 - Google Patents

칼슘 유동 작동제 및 이의 방법 Download PDF

Info

Publication number
KR20190038679A
KR20190038679A KR1020197009189A KR20197009189A KR20190038679A KR 20190038679 A KR20190038679 A KR 20190038679A KR 1020197009189 A KR1020197009189 A KR 1020197009189A KR 20197009189 A KR20197009189 A KR 20197009189A KR 20190038679 A KR20190038679 A KR 20190038679A
Authority
KR
South Korea
Prior art keywords
calcium
cells
agonist
tlr
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197009189A
Other languages
English (en)
Korean (ko)
Inventor
카이반 니아지
샤흐루즈 라비자데
저스틴 고로바토
패트릭 순-시옹
안-로르 르 나이
올렉산드르 버즈코
Original Assignee
난트 홀딩스 아이피, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 난트 홀딩스 아이피, 엘엘씨 filed Critical 난트 홀딩스 아이피, 엘엘씨
Publication of KR20190038679A publication Critical patent/KR20190038679A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020197009189A 2012-11-13 2013-11-13 칼슘 유동 작동제 및 이의 방법 Ceased KR20190038679A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725881P 2012-11-13 2012-11-13
US61/725,881 2012-11-13
PCT/US2013/069939 WO2014078447A1 (en) 2012-11-13 2013-11-13 Calcium flux agonists and methods therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032166A Division KR20170126031A (ko) 2012-11-13 2013-11-13 칼슘 유동 작동제 및 이의 방법

Publications (1)

Publication Number Publication Date
KR20190038679A true KR20190038679A (ko) 2019-04-08

Family

ID=50731660

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157015689A Ceased KR20150140625A (ko) 2012-11-13 2013-11-13 칼슘 유동 작동제 및 이의 방법
KR1020177032166A Ceased KR20170126031A (ko) 2012-11-13 2013-11-13 칼슘 유동 작동제 및 이의 방법
KR1020197009189A Ceased KR20190038679A (ko) 2012-11-13 2013-11-13 칼슘 유동 작동제 및 이의 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020157015689A Ceased KR20150140625A (ko) 2012-11-13 2013-11-13 칼슘 유동 작동제 및 이의 방법
KR1020177032166A Ceased KR20170126031A (ko) 2012-11-13 2013-11-13 칼슘 유동 작동제 및 이의 방법

Country Status (8)

Country Link
US (3) US9463184B2 (enExample)
EP (1) EP2919793B1 (enExample)
JP (2) JP6280129B2 (enExample)
KR (3) KR20150140625A (enExample)
CN (1) CN105188716B (enExample)
AU (1) AU2013344879B2 (enExample)
CA (1) CA2893276C (enExample)
WO (1) WO2014078447A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013344879B2 (en) * 2012-11-13 2016-04-28 Nant Holdings Ip, Llc Calcium flux agonists and methods therefor
CN113144197A (zh) * 2013-02-08 2021-07-23 罗达制药公司 治疗局部微生物感染的方法
US9884087B1 (en) * 2013-05-03 2018-02-06 Chan Soon-Shiong Nanthealth Foundation Compositions and methods of improved wound healing
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
CN108700566A (zh) * 2016-02-19 2018-10-23 河谷控股Ip有限责任公司 免疫原性调节的方法
JP6595746B2 (ja) * 2016-09-19 2019-10-23 フラー・ラボラトリーズ バベシア・ミクロチのインビトロ増殖
CN107496420B (zh) * 2017-08-25 2020-07-07 中国科学院微生物研究所 环匹阿尼酸类生物碱化合物的用途
US11969402B2 (en) 2019-05-16 2024-04-30 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111840560B (zh) * 2020-07-24 2021-09-03 广州医科大学 钙离子载体在白癜风治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960667A (en) 1972-03-23 1976-06-01 Eli Lilly And Company Antibiotic A23187 and process for preparation thereof
US3873693A (en) 1974-03-11 1975-03-25 Squibb & Sons Inc Ionomycin
US5489441A (en) * 1992-01-07 1996-02-06 Procept, Inc. Method for suppressing immune response associated with psoriasis, contact dermatitis and diabetes mellitus
US5238689A (en) * 1992-01-07 1993-08-24 Procept, Inc. Use of ruthenium red as immunosuppressive agents
TWI268153B (en) * 2004-06-23 2006-12-11 Univ Nat Cheng Kung A medicine composition for increasing leukocyte immunity wherein a leukocyte treated by sarcoplasmic/endoplasmic reticulum Ca2+ ATPase
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
US20080160116A1 (en) * 2006-12-07 2008-07-03 Herbalscience Singapore Pte. Ltd Compositions and Methods Comprising Zingiber Species
US20100105644A1 (en) * 2008-10-27 2010-04-29 The Regents Of The University Of Michigan Botanical composition for enhanced skin repair and uses thereof
CA2783244A1 (en) 2009-12-07 2011-06-16 Momentum Technologies, Inc. Nutrient yielding bio-renewable controlled release fertilizer coatings
WO2011115970A1 (en) 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
WO2012054792A2 (en) * 2010-10-22 2012-04-26 Virginia Commonwealth University Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
AU2013344879B2 (en) * 2012-11-13 2016-04-28 Nant Holdings Ip, Llc Calcium flux agonists and methods therefor

Also Published As

Publication number Publication date
JP2015537000A (ja) 2015-12-24
JP6280129B2 (ja) 2018-02-14
WO2014078447A1 (en) 2014-05-22
KR20150140625A (ko) 2015-12-16
EP2919793B1 (en) 2020-05-06
CN105188716B (zh) 2019-02-22
JP6625677B2 (ja) 2019-12-25
EP2919793A4 (en) 2016-06-01
US20170128568A1 (en) 2017-05-11
US20150297572A1 (en) 2015-10-22
US9750805B2 (en) 2017-09-05
KR20170126031A (ko) 2017-11-15
AU2013344879B2 (en) 2016-04-28
CN105188716A (zh) 2015-12-23
US20170360925A1 (en) 2017-12-21
CA2893276C (en) 2017-04-18
EP2919793A1 (en) 2015-09-23
CA2893276A1 (en) 2014-05-22
JP2018080199A (ja) 2018-05-24
US9463184B2 (en) 2016-10-11

Similar Documents

Publication Publication Date Title
JP6625677B2 (ja) カルシウムフラックスアゴニスト及びその方法
US10434142B2 (en) Compositions and methods of improved wound healing
Oršolić et al. Immunomodulation by water-soluble derivative of propolis: a factor of antitumor reactivity
AU2013344879A1 (en) Calcium flux agonists and methods therefor
CN101808627B (zh) 抗菌剂
Zhang et al. Puerarin prevents LPS-induced osteoclast formation and bone loss via inhibition of Akt activation
AU2012219321B2 (en) Compositions comprising peroxy alpha-ketocarboxylic acid and methods for producing and using the same
US20200297780A1 (en) Anti-inflammatory compositions, methods and uses thereof
Belkhelfa-Slimani et al. Caffeic acid and quercetin exert caspases-independent apoptotic effects on Leishmania major promastigotes, and reactivate the death of infected phagocytes derived from BALB/c mice
Qu et al. A rigid nanoplatform for precise and responsive treatment of intracellular multidrug-resistant bacteria
Nicolete et al. Leukotriene B4-loaded microspheres as a new approach to enhance antimicrobial responses in Histoplasma capsulatum-infected mice
RU2793626C2 (ru) Алкилрезорцины в качестве цитопротективного агента
RU2693228C2 (ru) Композит для ускоренного заживления ран различной этиологии, применение композита в качестве косметического средства и в качестве лечебного средства в ветеринарии, средство для регенерации кожных покровов на основе композита
CA2425025C (en) Use of bioactive fraction from cow urine distillate ('go mutra') as a bio-enhancer of anti-infective, anti-cancer agents and nutrients
WO2021076020A2 (ru) Фармацевтическая композиция для лечения и профилактики инфекционно-воспалительных заболеваний
Moreno-Eutimio et al. Potent Anti-Inflammatory Activity of Carbohydrate Polymer with Oxide of Zinc
HK1147441B (en) Antiseptics

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190329

Application number text: 1020177032166

Filing date: 20171107

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190429

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190728

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200428

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190728

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I